Characteristics | Case Number | High risk LLV case number (%) | p-value | Unadjusted analysis | Adjusted analysis | ||
---|---|---|---|---|---|---|---|
OR(95%CI) | p-value | aOR(95%CI) | p-Value | ||||
Gender | |||||||
 Male | 2001 | 142(7.10) | 0.957 | 1.00(reference) |  |  |  |
 Female | 125 | 8(6.40) |  | 1.03(0.24–4.38) | 0.967 |  |  |
 NA | 29 | 2(6.90) |  | 0.92(0.19–4.60) | 0.922 |  |  |
Age at HIV diagnosis | |||||||
 ≤ 50 (years) | 1618 | 110(6.80) | 0.607 | 1.00(reference) |  |  |  |
 >  50 (years) | 500 | 40(8.00) |  | 0.78(0.19–3.30) | 0.739 |  |  |
 NA | 37 | 2(5.41) |  | 1.19(0.82–1.74) | 0.361 |  |  |
Nation | |||||||
 Han | 1840 | 123(6.68) | 0.017 | 1.00(reference) |  | 1.00(reference) |  |
 Manchu | 195 | 24(12.31) |  | 1.96(1.23–3.12) | 0.005 | 2.03(1.27–3.25) | 0.003 |
 Others | 82 | 3(3.66) |  | 0.53(0.17–1.70) | 0.287 | 0.55(0.17–1.76) | 0.310 |
 NA | 38 | 2(5.26) |  | 0.78(0.19–3.26) | 0.729 | 0.60(0.10–3.64) | 0.579 |
Duration on ART | |||||||
 12–36(months) | 954 | 57(5.97) | 0.004 | 1.00(reference) |  | 1.00(reference) |  |
 36–60(months) | 674 | 41(6.08) |  | 1.02(0.67–1.54) | 0.928 | 1.02(0.67–1.54) | 0.925 |
 >  60(months) | 527 | 54(10.25) |  | 1.80(1.22–2.65) | 0.003 | 1.81(1.21–2.69) | 0.004 |
ART regimen | |||||||
 TDF + 3TC + EFV | 1477 | 84(5.69) | < 0.001 | 1.00(reference) |  | 1.00(reference) |  |
 AZT + 3TC + EFV | 276 | 20(7.25) |  | 1.30(0.78–2.15) | 0.315 | 1.31(0.79–2.18) | 0.301 |
 AZT + 3TC + NVP | 294 | 35(11.90) |  | 2.24(1.48–3.40) | < 0.001 | 2.26(1.48–3.45) | < 0.001 |
 D4T + 3TC + EFV | 41 | 5(12.20) |  | 2.30(0.88–6.02) | 0.089 | 2.38(0.90–6.33) | 0.082 |
 D4T + 3TC + NVP | 59 | 5(8.47) |  | 1.54(0.60–3.94) | 0.372 | 1.56(0.61–4.04) | 0.355 |
 DDI + a NRTI +a NNRTI | 8 | 3(37.50) |  | 9.95(2.34–42.34) | 0.002 | 9.96(2.33–42.49) | 0.002 |
Transmission route | |||||||
 Sexual | 1965 | 132(6.72) | 0.133 | 1.00(reference) |  | 1.00(reference) |  |
 Others | 24 | 2(8.33) |  | 1.26(0.29–5.43) | 0.754 | 1.31(0.30–5.67) | 0.715 |
 NA | 166 | 18(10.84) |  | 1.69(1.00–2.84) | 0.048 | 1.84(1.05–3.23) | 0.034 |
HIV-1 subtype | |||||||
 B | 130 | 7(5.38) | 0.001 | 1.00(reference) |  | 1.00(reference) |  |
 B′ | 20 | 6(30.00) |  | 7.53(2.22–25.57) | 0.001 | 8.22(2.34–28.92) | 0.001 |
 CRF01_AE | 1403 | 99(7.06) |  | 1.33(0.61–2.94) | 0.474 | 1.32(0.60–2.90) | 0.495 |
 CRF07_BC | 213 | 19(8.92) |  | 1.72(0.70–4.21) | 0.235 | 1.73(0.71–4.23) | 0.232 |
 Others | 95 | 4(4.21) |  | 0.77(0.22–2.72) | 0.687 | 0.77(0.22–2.73) | 0.690 |
 Na | 294 | 17(5.78) |  | 1.08(0.44–2.67) | 0.870 | 1.09(0.44–2.71) | 0.849 |
Zenith baseline VL | |||||||
 <  4 (log10 copies/ml) | 535 | 30(5.61) | 0.006 | 1.00(reference) |  | 1.00(reference) |  |
 4–5 (log10 copies/ml) | 1096 | 72(6.57) |  | 1.18(0.76–1.84) | 0.452 | 1.18(0.76–1.83) | 0.469 |
 5–6 (log10 copies/ml) | 472 | 41(8.69) |  | 1.60(0.98–2.61) | 0.059 | 1.58(0.96–2.58) | 0.070 |
 >  6 (log10 copies/ml) | 52 | 9(17.31) |  | 3.52(1.57–7.90) | 0.002 | 3.49(1.55–7.83) | 0.002 |
Nadir baseline CD4+ cell counts | |||||||
 >  350 (cells/ml) | 665 | 34(5.11) | 0.058 | 1.00(reference) |  | 1.00(reference) |  |
 200–350 (cells/mm3) | 805 | 57(7.08) |  | 1.41(0.91–2.19) | 0.121 | 1.41(0.91–2.19) | 0.123 |
 <  200 (cells/mm3) | 634 | 56(8.83) |  | 1.80(1.16–2.79) | 0.009 | 1.78(1.14–2.78) | 0.011 |
 NA | 51 | 5(9.80) |  | 2.02(0.75–5.40) | 0.163 | 2.03(0.76–5.43) | 0.160 |